FE65 as a link between VLDLR and APP to regulate their trafficking and processing by Dumanis, Sonya B et al.
RESEARCH ARTICLE Open Access
FE65 as a link between VLDLR and APP to
regulate their trafficking and processing
Sonya B Dumanis
1, Kelly A Chamberlain
1,2, Yoo Jin Sohn
1,2, Young Jin Lee
1,2, Suzanne Y Guénette
9,
Toshiharu Suzuki
4, Paul M Mathews
5, Daniel TS Pak
3, G William Rebeck
1, Yoo-hun Suh
6,7, Hee-Sae Park
8 and
Hyang-Sook Hoe
1,2*
Abstract
Background: Several studies found that FE65, a cytoplasmic adaptor protein, interacts with APP and LRP1, altering
the trafficking and processing of APP. We have previously shown that FE65 interacts with the ApoE receptor,
ApoER2, altering its trafficking and processing. Interestingly, it has been shown that FE65 can act as a linker
between APP and LRP1 or ApoER2. In the present study, we tested whether FE65 can interact with another ApoE
receptor, VLDLR, thereby altering its trafficking and processing, and whether FE65 can serve as a linker between
APP and VLDLR.
Results: We found that FE65 interacted with VLDLR using GST pull-down and co-immunoprecipitation assays in
COS7 cells and in brain lysates. This interaction occurs via the PTB1 domain of FE65. Co-transfection with FE65 and
full length VLDLR increased secreted VLDLR (sVLDLR); however, the levels of VLDLR C-terminal fragment (CTF) were
undetectable as a result of proteasomal degradation. Additionally, FE65 increased cell surface levels of VLDLR.
Moreover, we identified a novel complex between VLDLR and APP, which altered trafficking and processing of
both proteins. Furthermore, immunoprecipitation results demonstrated that the presence of FE65 increased the
interaction between APP and VLDLR in vitro and in vivo.
Conclusions: These data suggest that FE65 can regulate VLDLR trafficking and processing. Additionally, the
interaction between VLDLR and APP altered both protein’s trafficking and processing. Finally, our data suggest that
FE65 serves as a link between VLDLR and APP. This novel interaction adds to a growing body of literature
indicating trimeric complexes with various ApoE Receptors and APP.
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Background
FE65 and FE65-like (FE65L or FE65L1) proteins are cyto-
plasmic adaptor proteins that possess two phosphotyrosine
binding domains (PTB1 and PTB2) and one WW binding
domain. FE65 is primarily found in the CNS and is highly
expressed in neurons of the hippocampus, cerebellum,
thalamus, and brainstem nuclei in the adult mouse brain
[1]. Several studies have shown that FE65 can form a
stable, transcriptionally active complex with AICD (APP
intracellular domain) in heterologous gene reporter sys-
tems [2-8], although the full range of gene targets is still
unknown. FE65 is functionally linked to cellular motility
and morphology and actin dynamics through binding of
its WW domain to the actin-binding protein Mena [9,10].
Interestingly, FE65 and FE65L double knockout mice exhi-
bit defects similar to triple APP knockout (APP tKO):
lissencephaly and selected axonal projection defects [11].
The PTB2 domain of FE65 interacts with the NPXY
motif of amyloid precursor protein (APP) [12-14] and this
interaction mediates APP trafficking both in vitro and in
vivo [13,15]. For example, in H4 neuroglioma cells, the
induction of hFE65L increased the ratio of mature to total
APP levels and increased secreted APPa (sAPPa) three-
fold [13]. Similar results were obtained in Madin-Darby
Canine Kidney (MDCK) cells where overexpression of
FE65 led to increased translocation of APP to the cell
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tion, [16]. In contrast to the H4 and MDCK cells, overex-
pression of full-length FE65 strongly decreased secreted
APPa and APP C-terminal fragment (CTF) in CHO cells
[17,18]. Overexpressing human FE65 in a Thy-1 APP
transgenic mouse model also resulted in decreased Ab
accumulation in the cerebral cortex and decreased levels
of APP CTF [14]. Therefore, it is unclear how FE65 could
modulate APP trafficking and processing.
The PTB1 domain of FE65 interacts with ApoE recep-
tors, including LRP1 and ApoER2, via the ApoE receptor’s
NPXY motif [17,19]. Moreover, FE65 acts as a functional
linker between LRP1 and APP [20,21]. Overexpression of
FE65 increased sAPP in LRP+/+ mouse fibroblasts; how-
ever, no significant effect on APP processing exists in
LRP-/- fibroblasts, suggesting the effect of FE65 on APP
processing is LRP dependent [20]. In a recent study, we
have shown that a similar tripartite complex is formed
between APP, FE65, and ApoER2 and that LRP1 may be
competing with ApoER2 for FE65 binding sites [17]. This
complex results in altered processing of both APP and
ApoER2. Overexpression of FE65 led to a significant
increase in secreted ApoER2, secreted ApoER2 CTF, and
cell surface levels of ApoER2 in COS7 cells [17]. Whether
FE65 can interact with other ApoE receptors, affecting
receptor trafficking and processing, is unknown.
In the present study, we demonstrated a novel interac-
tion between FE65 and VLDLR (very low density lipopro-
tein receptor) using a GST pull-down assay in brain
lysates. Co-immunoprecipitation studies indicated that
there was also a complex formed between APP and
V L D L R ,w h i c hi si n c r e a s e di nt h ep r e s e n c eo fF E 6 5in
vitro and in vivo. This data suggests that FE65 acts as a lin-
ker between VLDLR and APP. Moreover, we found that
these interactions modulate APP and VLDLR trafficking
and processing.
Results
FE65 interacts with VLDLR
We used co-immunoprecipitation experiments to test
whether FE65 interacted with VLDLR. COS7 cells were
transfected with VLDLR and empty vector, VLDLR and
FE65, or FE65 and empty vector. Full-length VLDLR co-
precipitated with FE65 and was not detectable in the
absence of FE65 (Figure 1A). Western blot analysis of
COS7 cell extracts confirmed that levels of VLDLR and
FE65 were consistent across transfections (Figure 1A). We
also performed the reverse experiment, which showed that
full-length FE65 co-precipitated with VLDLR and was not
detectable in the absence of VLDLR (Figure 1B).
To test whether VLDLR CTF interacted with FE65, we
transfected COS7 cells with full length VLDLR and
empty vector, full length VLDLR and FE65, or VLDLR
CTF and FE65 (Figure 1C, D), and performed co-
immunoprecipitations. We found that FE65 co-precipi-
tated with both full length VLDLR and VLDLR CTF
(Figure 1E). Consistent with these findings, the reverse
experiment resulted in co-precipitation of full length
VLDLR and VLDLR CTF with FE65 in COS7 cells
(Figure 1F).
We then examined whether there was a physical asso-
ciation between FE65 and VLDLR in vivo.T ot e s tt h i s ,
we performed co-immunoprecipitations from whole brain
lysates, using anti-5F3 to recognize VLDLR or a nonspe-
cific IgG as a negative control. Immunoprecipitation of
VLDLR resulted in the co-precipitation of FE65 (Figure
1G). In the reverse experiment, we performed co-immu-
noprecipitation from whole brain lysates using anti-FE65
and then probed with anti-5F3. We found that FE65 co-
immunoprecipitated with both the mature and immature
forms of VLDLR in brain lysates (Figure 1H). Overall,
these results suggest that VLDLR interacts with FE65
both in vitro and in vivo. To further examine whether
VLDLR interacts with FE65, we incubated wild-type brain
lysates with purified immobilized GST or GST-VLDLR
CTF protein and probed for FE65 (Figure 1 I-K). We
found that VLDLR CTF interacted with FE65 in vivo.N o
signal was detected in lanes of brain lysates incubated
with GST alone.
FE65 co-localizes with VLDLR in primary hippocampal
neurons
To test whether endogenous FE65 co-localizes with
VLDLR during early neuronal development, primary hip-
pocampal neurons (DIV 3) were fixed and immunostained
with anti-5F3 and anti-FE65 antibodies. VLDLR and FE65
immunoreactivities were strong in the cell body and punc-
tuate throughout neuronal processes (Figure 2A). The
immunostainings overlapped suggesting that VLDLR co-
localized with FE65 within the cell bodies and partially co-
localized in neuronal processes (Figure 2A).
To test whether FE65 and VLDLR can still co-localize
during the peak of synaptogenesis, primary hippocampal
neurons (DIV 14) were fixed and immunostained with
anti-5F3 and anti-FE65 antibodies. Interestingly, FE65
expression was up-regulated on DIV 14 compared to
DIV3, consistent with previous findings [1]. Moreover,
VLDLR and FE65 immunoreactivity was strong in the cell
body and punctuate throughout neuronal processes with
partial co-localizations, consistent with what we observed
on DIV 3 (Figure 2B).
VLDLR interacts with the PTB1 domain of FE65
To determine which domain of FE65 interacts with
VLDLR, COS7 cells were co-transfected with full length
VLDLR and FE65 deletion constructs containing a c-
terminal myc tag (Figure 3A). Each FE65 construct
resulted in protein expression at the anticipated sizes, as
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Page 2 of 15Figure 1 FE65 interacts with VLDLR in COS7 cells and brain lysates. A. COS7 cells were transiently transfected with VLDLR (HA-tagged on the C
terminal) and FE65 (myc-tagged on the C terminal), or each construct alone with empty vector. Cell lysates (200 ug) were immunoprecipitated with
anti-myc and the precipitate was probed with anti-HA. FE65 co-precipitated with VLDLR in COS7 cells (lane 3, upper panel). Cell lysates (20 ug) were
probed for VLDLR and FE65 to demonstrate consistent levels of expression across each condition (middle and lower panel). B.C O S 7c e l l sw e r e
transfected with VLDLR (HA-tagged) and FE65 (myc-tagged), or each construct alone. Cell lysates (200 ug) were immunoprecipitated with anti-HA and
the precipitate was probed with anti-myc. VLDLR co-precipitated with FE65 in COS7 cells (lane 3, upper panel). Cell lysates (20 ug) were probed for
VLDLR and FE65 to demonstrate consistent levels of expression across conditions (middle and lower panel). C. VLDLR deletion construct expressing
the CTF of VLDLR with an HA tag was generated. D. COS7 cells were transiently transfected with VLDLR or VLDLR CTF constructs. Cell lysates (20 ug)
were probed for anti-HA to verify the expression of constructs. E-F. COS7 cells were transiently transfected with full length VLDLR and empty vector,
full length VLDLR and FE65 or VLDLR CTF and FE65. E. Cell lysates (200 ug) were immunoprecipitated with anti-myc and the precipitate was probed
with anti-HA. VLDLR CTF and full length VLDLR co-precipitated with FE65 in COS7 cells (lane 2 and 3, upper panel). Cell lysates (20 ug) were probed for
FE65 to demonstrate consistent levels of expression across each condition (lower panel). F. Cell lysates (200 ug) were immunoprecipitated with anti-
HA and the precipitate was probed with anti-myc. FE65 immunoprecipitated with both VLDLR constructs consistent with the experiment in E. G.
Mouse brain lysates (100 ug) were immunoprecipitated with 5F3 (VLDLR antibody) or Ig G and probed with anti-VLDLR (upper panel) and anti-FE65
(lower panel). H. Mouse brain lysates (100 ug) were immunoprecipitated with anti-FE65 or IgG and probed with anti-FE65 (upper panel) and anti-
VLDLR (lower panel). I. Schematic of recombinant GST-VLDLR CTF J. The recombinant GST-VLDLR CTF was expressed in E.coli strain BL21, using the
pGEX system as indicated. The GST fusion proteins were then purified using glutathione-agarose beads (Sigma), in accordance with the manufacturer’s
instructions. (I, total cell extract of induced cells; S, supernatant of sonicated extracts of induced cells (soluble recombinant protein); P, Pellet of
sonicated extracts of induced cells (insoluble recombinant protein); E, Purified VLDLR CTF proteins). K. Recombinant GST-VLDLR CTF proteins were
immobilized onto GSH-agarose. Wild-type brain lysates were then subjected to GST-pull-down experiments with either immbolized GST (lane 1, 3) or
immobilized GST-VLDLR CTF (lane 2, 4) and probed for FE65.
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Page 3 of 15Figure 2 FE65 co-localizes with VLDLR in primary hippocampal neurons. A. After 3 days in culture, primary hippocampal neurons were
fixed and immunostained for 5F3 (recognizing VLDLR) and anti-FE65. Antibodies were detected with Alexa Flour 488 anti-mouse antibody (in
green for VLDLR) and Alexa Fluor 555 anti-rabbit antibody (in red for FE65), imaged with a confocal laser-scanning microscope (63X). Co-
localization of VLDLR and FE65 appears yellow as vesicular staining in the right panel. B. After 14 days in culture, primary hippocampal neurons
were fixed and immunostained for 5F3 (recognizing VLDLR) and anti-FE65. Antibodies were detected with Alexa Flour 488 anti-mouse antibody
(in green for VLDLR) and Alexa Fluor 555 anti-rabbit antibody (in red for FE65), observed with a confocal laser-scanning microscope (63X). Co-
localization of VLDLR and FE65 appears yellow as vesicular staining in the right panel, consistent with Figure 2A.
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Page 4 of 15determined by western blot (Figure 3B, upper panel).
VLDLR was expressed to similar levels in all transfected
cells (Figure 3B, lower panel). Immunoprecipitation with
an anti-HA antibody (for VLDLR) and probing with an
anti-myc antibody (for FE65) resulted in VLDLR immu-
noprecipitation with all three FE65 constructs contain-
ing the PTB1 domain, but not the FE65 containing only
the PTB2 domain construct (Figure 3C, upper panel).
Interestingly, VLDLR interacted strongly with the FE65
construct lacking the WW domain (construct #1) com-
pared to full length FE65 (construct #4) and the FE65
construct containing only the WW and PTB1 domains
(construct #2) (Figure 3C). However, the FE65 WW
domain alone does not co-precipitate with VLDLR (data
not shown). Since it has been shown that the WW and
PTB domains of FE65 can interact with each other [3],
the FE65 WW domain may induce conformational
changes in full length FE65 which reduce the exposure
of the FE65 PTB1 domain for interaction with VLDLR.
We conducted an additional experiment to ensure that
the lack of co-immunoprecipitation between VLDLR
and the FE65 containing only the PTB2 domain was not
due to the decreased expression level of the FE65 PTB2
domain (construct #3) in cell lysates. To test this, we
used a different set of FE65 deletion constructs, which
have a GFP c-terminal tag. COS7 cells were co-trans-
fected with full length VLDLR-myc and GFP, VLDLR-
myc and FE65 PTB2-GFP (construct #1), or VLDLR-
myc and full length FE65-GFP (construct #2) (Addi-
tional file 1: Figure S1A). VLDLR and each FE65 con-
struct resulted in similar protein expression in all
transfected cells (Additional file 1: Figure S1B). Immu-
noprecipitation with an 5F3 antibody (for VLDLR) and
probing with an anti-GFP antibody (for FE65) resulted
in full length FE65 immunoprecipitation with the
VLDLR but the FE65 construct containing only the
PTB2 domain did not. Consistent with these findings,
the reverse experiment resulted in co-precipitation of
VLDLR with the full but not with the truncated PTB2
construct (Additional file 1: Figure S1B).
FE65 affects VLDLR processing
Our previous studies have shown that VLDLR under-
goes a-a n dg- secretase cleavage similar to APP and
ApoER2 [22]. Because VLDLR CTFs were undetectable
with overexpression of full length VLDLR, we hypothe-
sized that VLDLR CTF may undergo proteasome degra-
dation. To test this possibility, COS7 cells were
transfected with full length VLDLR and treated with the
proteasomal inhibitor, MG132 (10 uM) or vehicle (10%
DMSO) for 24 hours. We found that VLDLR CTFs were
detectable when full length VLDLR-transfected cells
were treated with MG132 (Figure 4A). Interestingly,
there was also a large increase in full length VLDLR
suggesting that both VLDLR CTFs and full length
VLDLR undergo proteasomal degredation.
To test whether FE65 could modulate VLDLR proces-
sing in vitro, COS7 cells were transfected with VLDLR-
HA and empty vector or VLDLR-HA and FE65, and the
levels of sVLDLR, total VLDLR, and VLDLR CTF were
measured. Co-transfection of FE65 increased sVLDLR
Figure 3 VLDLR interacts with the PTB1 domain of FE65 A.
Constructs of FE65 with C-terminal Myc tags containing PTB1 and
PTB2 (construct 1, ~65 KD), WW and PTB1 (construct 2, ~85 KD),
only PTB2 (construct 3, ~15 KD), and full length FE65 (construct 4,
~95 KD). B. Western blot analysis showing comparable expression
levels of the different FE65 constructs (upper panel). The VLDLR
immunoblotting (bottom panel) showed similar expression levels of
VLDLR in all transfected cells. C. COS7 cells were transfected with
plasmids expressing different FE65 constructs (indicated along the
top of the panel) and full length VLDLR. Cell lysates (200 ug) were
immunoprecipitated with anti-HA antibody (for VLDLR) and probed
with an anti-myc antibody (for FE65). FE65 constructs containing the
PTB1 domain (constructs 1, 2, 4) co-immunoprecipitated with
VLDLR, but not constructs containing only the PTB2 domain
(construct 3).
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Page 5 of 15Figure 4 FE65 increases cell surface levels of VLDLR A. COS7 cells were transiently transfected with full length VLDLR for 24 hours. After
transfection, cells were grown in serum-free media and incubated with MG132 (10 uM) (lane 2) or DMSO (lane 1) as control for 24 hr. Cell
lysates (20 ug/lane) were then probed with anti-HA antibody. Consistent with previous findings, VLDLR CTFs were only detectable in the
presence of MG132. B. COS7 cells were transiently transfected with VLDLR and empty vector or VLDLR and FE65. Secreted VLDLR was measured
in conditioned media (14 ul) with 5F3 antibody. Total VLDLR and VLDLR CTF were measured in cell lysates (20 ug/lane) with anti-HA. FE65
increased levels of sVLDLR, suggesting that FE65 affects VLDLR processing. C. COS7 cells were transfected with VLDLR and vector (lanes 1, 3) or
VLDLR and FE65-myc (lanes 2, 4). Cell surface proteins were biotin-labeled, isolated with avidin-beads, and immunoblotted with the 5F3 antibody
for VLDLR detection. Full length FE65 increased surface levels of VLDLR (upper blot). Expression of VLDLR across all transfections in shown in the
lower blot. D. Quantification of surface levels of VLDLR normalized to control in (C). FE65 increases cell surface levels of VLDLR by 118% (n = 4, p
< 0.001). E. Cultured hippocampal neurons (DIV14) were transfected with GFP, VLDLR, and empty vector (upper panel) or GFP, VLDLR, and FE65
(lower panel). Surface VLDLR was measured with the 5F3 antibody by immunofluorescence of live cells. F. Quantification of cell surface VLDLR
intensity in neuronal processes in (E). The cell surface staining in neuronal processes showed a 1.2 fold increase in cell surface levels of VLDLR
with FE65 (n = 10, p < 0.05). G. Cultured hippocampal neurons (DIV14) were transfected with GFP, VLDLR, and empty vector (upper panel) or
GFP, VLDLR, and FE65 (lower panel). Total levels of VLDLR were measured with the 5F3 antibody by immunofluorescence after permeabilization
of cells. H. Quantification of total VLDLR intensity in neuronal processes in (G).
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Page 6 of 15(Figure 4B, upper panel) and had no effect on total
VLDLR levels in COS7 cells (Figure 4B, lower panel).
VLDLR CTFs were still undetectable in the presence of
FE65. These data suggest that FE65 may regulate
VLDLR processing.
FE65 increases cell surface levels of VLDLR
To test whether FE65 could affect VLDLR trafficking, we
transfected COS7 cells with full length VLDLR and empty
vector or full length VLDLR and FE65 for 24 hours. Cell
surface proteins were biotinylated, isolated with avidin
beads, and immunoblotted for VLDLR. We found that
FE65 significantly increased cell surface levels of VLDLR
by 118% (Figure 4C, D, n = 4/condition). To verify our
findings, we conducted live cell surface staining by overex-
pressing GFP, VLDLR and empty vector or GFP, VLDLR
and FE65 in primary hippocampal neurons (DIV 14-16).
FE65 increased cell surface levels of VLDLR by 120%, a 1.2
fold increase, in primary hippocampal neurons (Figure 4E,
F, p < 0.05; n = 10). However, total VLDLR protein level
was unchanged in the presence of FE65, consistent with
our previous in vitro and in vivo data (Figure 4G, H).
Thus, two independent assays suggest that FE65 can mod-
ulate cell surface expression of VLDLR.
FE65 and VLDLR CTF translocate into the nucleus
Several studies have shown that FE65 and the cytoplas-
mic domain of APP form a complex and translocate
into the nucleus in COS7 and H4 cells [2,3,23,24]. Con-
sistent with previous findings, we observed that APP
CTF was present in nuclear fractions when co-expressed
with FE65 compared to controls (Figure 5A). We then
examined whether FE65 could also translocate VLDLR
CTFs to the nucleus. To test this, we transfected COS7
cells with full length VLDLR or VLDLR CTF with either
FE65 or empty vector. We found that full length
VLDLR and FE65 were present in the cytosol/membrane
fractionation, but were not present in the nucleus
(Figure 5B). Similar to APP CTF and FE65 complex,
VLDLR CTF and FE65 were expressed in both the cyto-
solic/membrane and in the nucleus (Figure 5C).
VLDLR interacts with APP and affects processing of both
proteins
ApoE Receptors, including LRP1 and ApoER2, have been
shown to interact with APP [17,19-21,25], and thus we
wanted to investigate whether VLDLR can interact with
APP. For this experiment, we performed co-immunopre-
cipitations from whole brain lysates using anti-VLDLR
antibody or an anti-IgG antibody and probed for APP.
We observed that APP co-precipitated with VLDLR in
vivo (Figure 6A, upper panel). We also conducted the
reverse experiment and found that VLDLR co-precipi-
tated with APP (Figure 6B). APP and VLDLR were
expressed to similar levels in all conditions (Figure 6A, B
lower panels).
To examine the effect of APP on VLDLR processing, we
transfected COS7 cells with full length VLDLR and empty
vector or full length VLDLR and APP, and then the levels
of sVLDLR, total VLDLR, VLDLR CTF, and total APP
were measured. Co-transfection with APP resulted in
increased sVLDLR and total VLDLR compared to empty
vector (Figure 6C). However, VLDLR CTF levels remained
undetectable.
Next, COS7 cells were transfected with APP and empty
vector or APP and VLDLR in order to examine the effect
of VLDLR on APP processing. VLDLR increased the levels
of total APP, sAPPa and APP CTF (Figure 6D). These
data suggest that the interaction between APP and
VLDLR affects the metabolism of both proteins.
VLDLR and APP affect cell surface expression of each
other
We next examined whether APP alters cell surface expres-
sion of VLDLR. COS7 cells were transfected with VLDLR
and empty vector or VLDLR and APP, and cell surface
biotinylation was performed. We found that APP
increased cell surface levels of VLDLR (Figure 7A). We
also examined whether VLDLR can regulate cell surface
expression of APP. COS7 cells were transfected with APP
and empty vector or APP and VLDLR. We found that
VLDLR increased cell surface levels of APP (Figure 7B).
To further examine the effects of VLDLR on APP traffick-
ing, primary hippocampal neurons were transfected with
GFP, APP, and empty vector or GFP, APP, and VLDLR
and live cell surface staining was conducted. Consistent
with our findings, VLDLR significantly increased cell sur-
face levels of APP by 24% (p < 0.05, n = 10) (Figure 7C, D).
FE65 increases interaction between VLDLR and APP in
vitro and in vivo
We and others have shown that FE65 forms tripartite
complexes with APP and LRP1 or ApoER2, modulating
the interaction of these proteins [17,20]. We investigated
whether FE65 can affect the interaction between VLDLR
and APP in vitro. COS7 cells were transfected with
VLDLR, APP, and empty vector or VLDLR, APP, and
FE65. Immunoprecipitation with an anti-VLDLR antibody
and probing for APP revealed that FE65 increased the
interaction between VLDLR and APP in COS7 cells
(Figure 8A). In the reverse experiment, co-transfection
with FE65 increased the association between APP and
VLDLR (Figure 8B).
To verify whether FE65 can modulate the interaction
between APP and VLDLR, we transfected COS7 cells
with APP, VLDLR and either full length FE65 or FE65
PTB2 domain, which interacts with APP but not
VLDLR. Cell lysates were immunoprecipitated with an
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Page 7 of 15Figure 5 FE65 and VLDLR CTF complex translocates into the nucleus. A. COS7 cells were transfected with APP CTF and vector or APP CTF
and FE65 and cellular fractionation was conducted. Cytoplasmic/Membrane (CM) and nuclear (N) fractions were immunoblotted with the C1/6.1
antibody (for APP) and the anti-myc antibody (for FE65). B. COS7 cells were transfected with full length VLDLR and vector or full length VLDLR
and FE65 and cellular fractionation was conducted. Cytoplasmic/Membrane (CM) and nuclear (N) fractions were immunoblotted with the 5F3
antibody (for VLDLR) and the anti-myc antibody (for FE65). C. COS7 cells were transfected with VLDLR CTF and vector or VLDLR CTF and FE65
and cellular fractionation was conducted. Cytoplasmic/Membrane (CM) and nuclear (N) fractions were immunoblotted with the anti-HA antibody
(for VLDLR CTF) and the anti-myc antibody (for FE65).
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Page 8 of 15anti-5F3 antibody (for VLDLR) and probed with an anti-
22C11 antibody (for APP) (Figure 8C). We found that
FE65 PTB2 domain construct significantly decreased the
association between APP and VLDLR compared to full-
length FE65 (Figure 8C). To examine whether FE65 can
alter the association between APP and VLDLR in vivo,
we immunoprecipitated VLDLR from brain lysates and
found that an APP immunoreactive band was decreased
in FE65 knockout brain lysates compared to wild-type
littermates (Figure 8D). These data further demonstrate
that FE65 is a linker between APP and VLDLR.Total
levels of VLDLR were unchanged in FE65 knockout
mice compared to wildtype littermates. (Figure 8D,
lower panel). Interestingly, FE65 knockout mice had sig-
nificantly increased total APP and APP CTFs compared
to wild-type littermates (Figure 8D, Additional file 2:
Figure S2). These data indicate that FE65 may also dif-
ferentially regulate the processing of APP and VLDLR.
Discussion
Previous studies have shown that FE65 interacts with
ApoE receptors, LRP1 [19] and ApoER2 [17,25]. In the
present study, we discovered a novel interaction between
FE65 and VLDLR using GST pull-down and co-
immunoprecipitation assays (Figure 1). We have pre-
viously shown that FE65 increased cell surface levels of
ApoER2 in vitro [17]. In that same study, we found that
FE65 increased sApoER2 and ApoER2 CTF in COS7
cells, while knockdown of FE65 caused decreased
ApoER2 CTF in vivo [17]. However, whether FE65 can
alter LRP1 trafficking and processing is unknown.
In this study, we examined the effects of FE65 on
VLDLR trafficking and processing and found that FE65
increases VLDLR on the cell surface in vitro (Figure 4),
similar to the effect of FE65 on ApoER2 trafficking [17]. In
addition, FE65 increased sVLDLR, while total VLDLR
remained unchanged in COS7 cells (Figure 4) and brain
lysates (Figure 8D). Consistent with our previous findings
[17], VLDLR CTF was undetectable without the presence
of the proteasomal inhibitor MG132 when full length
VLDLR was overexpressed. Additionally, we observed
increased expression of full length VLDLR with MG132
treatment, suggesting that both VLDLR CTF and full
length VLDLR may undergo proteasome degradation (Fig-
ure 4A). To further support our findings, a recent study
demonstrated that the E3 ubiquitin Ligase IDOL targets
the VLDLR receptor for degradation, specifically through
the lysine residues adjacent to the NPXY motif [26].
Figure 6 VLDLR interacts with APP and affects the processing of both proteins. A. Mouse brain lysates (100 ug) were immunoprecipitated
with 5F3 (VLDLR antibody) or IgG antibody and probed with the C1/6.1 antibody for APP. B. Mouse brain lysates (100 ug) were
immunoprecipitated with C1/6.1 (APP antibody) or IgG antibody and probed with 5F3 antibody for VLDLR. C. COS7 cells were transfected with
VLDLR-myc and vector (lanes 1, 3, 5) or VLDLR-myc and APP-HA (lanes 2, 4, 6). Secreted VLDLR was measured in conditioned media with 5F3
antibody, and total levels of VLDLR and APP were measured in cell lysates with anti-myc antibody and C1/6.1, respectively. D. COS7 cells were
transfected with APP and vector (lanes 1, 3, 5) or APP and VLDLR (lanes 2, 4, 6). Secreted APP was measured in conditioned media with 6E10
antibody, and total levels of APP and APP CTF were measured in cell lysates with C1/6.1. Total levels of VLDLR were measured in cell lysates
with anti-myc antibody.
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FE65 interacts with APP, thereby affecting its trafficking
and processing in numerous cell lines [12-14,27-30].
These studies have differed in the observed effects of
FE65 on APP processing. We found that FE65 increased
sAPPa and decreased Ab production in COS7 cells [17],
perhaps by modulating APP trafficking. In contrast, we
and others have shown that FE65 decreased sAPPa in
CHO cells [17,18], suggesting that the effects in different
cell types may be due to different interacting proteins.
Guenette et al. examined the effect of FE65 on APP pro-
cessing in vivo and found that total APP levels were
unchanged in 3-4 month old FE65 knockout mice com-
pared to wild-type littermates [11]. Interestingly, we
observed that 13 month old FE65 knockout mice have an
increase total APP and APP CTF compared to wild-type
littermates (Additional file 1: Figure S1), suggesting that
FE65 alters APP processing in an age-dependent manner.
Several studies have shown that FE65 complexes with
APP CTF or AICD resulting in translocation of this
complex, along with Tip60, to the nucleus where they
likely participate in gene transcription events [2,3,23,26].
Also, over-expression of LRP1 intracellular domain (LRP
ICD) and FE65 resulted in translocation of these pro-
teins into the nucleus, which inhibited transcription
activation mediated by the APP and FE65 complex [23].
However, whether the ApoER2 CTF and FE65 complex
can translocate into the nucleus is unknown. Consistent
with previous findings, we found that APP CTF and
FE65 resulted in localization of the nuclear fraction (Fig-
ure 5A). Additionally, we observed that co-expression of
FE65 and VLDLR CTF resulted in translocations of
FE65 and VLDLR CTF in the nucleus (Figure 5C). This
data suggest that similar to APP CTF and FE65, VLDLR
C T Fa n dF E 6 5t r a n s l o c a t ei n t ot h en u c l e u st op l a ya
role in gene transcription. It is possible that VLDLR
CTF and FE65 may inhibit APP CTF/FE65 transcrip-
tional activation, similar to LRP ICD [24]. Future studies
are required to understand the biological significance of
this translocation; genes may be preferentially regulated
Figure 7 The interaction between APP and VLDLR regulates the cell surface levels of both proteins. A. COS7 cells were transfected with
VLDLR and vector (lanes 1, 3) or VLDLR and APP (lanes 2, 4). Cell surface proteins were biotin-labeled, isolated with avidin-beads, and
immunoblotted for VLDLR. APP increased surface levels of VLDLR (upper blot). B. COS7 cells were transfected with APP and vector (lanes 1, 3) or
APP and VLDLR (lanes 2, 4). Cell surface proteins were biotin-labeled, isolated with avidin-beads, and immunoblotted for APP. VLDLR increased
surface levels of APP (upper blot). C. Cultured hippocampal neurons (DIV14) were transfected with GFP, APP, and empty vector (upper panel) or
GFP, APP, and VLDLR (lower panel). Surface APP was measured with an anti-APP antibody by immunofluorescence of live cells. D. Quantification
of cell surface APP intensity in neuronal processes in (C). The cell surface staining in neuronal processes showed a 24% increase in APP by VLDLR
(n = 10, p < 0.05).
Dumanis et al. Molecular Neurodegeneration 2012, 7:9
http://www.molecularneurodegeneration.com/content/7/1/9
Page 10 of 15by VLDLR CTF and FE65 compared to APP CTF or
LRP ICD and FE65.
Numerous studies have shown that the ApoE receptors
interact with APP directly or indirectly through FE65
[17,19-21,25]; thus, we examined whether a similar inter-
action occurs between APP and VLDLR. We found that
VLDLR co-precipitated with APP in brain lysates and vice
versa, suggesting that these proteins may form a complex
in vivo (Figure 6A, B). Several studies have shown that
ApoE receptors including ApoER2, LRP1, LRP1B, SORL1
and LRAD3 regulate APP trafficking and processing
[18,23,31-37]. For example, LRP1 and LRP1B have been
directly linked to the formation of Ab in vitro [18,31-33]
and disruption of LRP1 and LRP1B with APP interaction
Figure 8 FE65 increased co-precipitation of APP and VLDLR. A. COS7 cells were transfected with APP-v5, empty vector, and VLDLR-HA or
APP-v5, FE65-GFP, and VLDLR-HA. Cell lysates were immunoprecipitated with anti-HA antibody (for VLDLR) and probed with anti-V5 (for APP).
Immunoblots of cell lysates showed similar levels of APP and VLDLR. B. COS7 cells were transfected with APP, empty vector, and VLDLR or APP,
FE65, and VLDLR. Cell lysates were immunoprecipitated with anti-V5 antibody (for APP) and probed with anti-HA (for VLDLR). Immunoblots of
cell lysates showed similar levels of APP and VLDLR. C. COS7 cells were transfected with APP, VLDLR and either full length FE65-GFP or FE65-
PTB2 domain-GFP. Cell lysates were immunoblotted with anti- GFP antibody (for FE65 constructs), VLDLR, APP and b-actin was used as the
loading control (lower panels). Cell lysates were immunoprecipitated with anti-5F3 (for VLDLR) and probed for anti-22C11 (for APP) (top panel). n
= 3 per condition. D. Brain lysates from FE65 knockout mice and wild-type littermates were immunoprecipitated with anti-5F3 and
immunobloted for anti-C1/6.1. Immunoblots for total levels of APP (C1/6.1), VLDLR (IIII) and FE65 are in the lower panels.
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reduced Ab production [34]. Overexpression of ApoER2
results in increased cell surface levels of APP, increased
Ab production, and a reduction in APP CTFs in vitro [35].
In contrast, our study has shown that ApoER2 significantly
increased cell surface levels of APP, increased sAPPa,a n d
decreased Ab levels [22]. SORL1, another member of the
ApoE receptor family, has also been implicated in APP
trafficking [36]. Additionally, a recently discovered ApoE
receptor, LRAD3, has also been shown to interact with
APP and affect APP processing by decreasing sAPPa and
increasing Ab production [37]. Interestingly, FE65 does
not interact with LRAD3 suggesting that there are multi-
ple pathways by which ApoE receptors can influence APP
processing and trafficking.
In the present study, we investigated whether VLDLR
could also affect APP trafficking and processing. We
found that full length VLDLR increased cell surface levels
of APP (Figure 7B) as well as the levels of sAPPa and APP
CTF in COS7 cells (Figure 6D). This is consistent with
previous studies, which have found that retention of APP
at the cell surface increases sAPPa production [38,39].
Conversely, we found that co-transfection of VLDLR with
APP resulted in increased cell surface levels of VLDLR
(Figure 7A) as well as levels of sVLDLR (Figure 6C), sug-
gesting that the VLDLR/APP complex is retained at the
cell surface where it can be cleaved by a-secretase. Sur-
prisingly, co-expression of APP and VLDLR increased the
total levels of both molecules( F i g u r e7 A ,B ) .S i n c ew e
observed that full length VLDLR undergoes proteosomal
degradation (Figure 4C), perhaps the interaction between
APP and VLDLR slows down its proteosomal degradation
resulting in increased total protein expression. Taken
together, these data suggest that ApoE receptors associate
with APP and these interactions regulate APP trafficking
and processing and vice versa. However, whether this
effect is due to a direct interaction or modulation by cyto-
plasmic adaptor proteins, such as FE65, is unknown.
We and others have shown that FE65 can functionally
l i n kA P Pw i t hA p o E r 2a n dL R Pa n dt h a tt h i sc o m p l e x
modulates both the ApoE receptor and APP trafficking
and processing [17,18,31-33]. Here, we examined whether
FE65 could form an intracellular link between APP and
VLDLR and found that full length FE65 increased co-pre-
cipitation of APP with VLDLR in vitro (Figure 8A, B) and
in vivo (Figure 8D), suggesting that FE65 serves as a link
between APP and VLDLR. Interestingly, our recent study
showed that ApoEr2 and LRP1 can compete for binding
of FE65 [17] to alter APP trafficking and processing. Thus,
it is possible that VLDLR may compete with other ApoE
receptors to bind to FE65, and consequently alter APP
trafficking and processing. Future studies will clarify under
which conditions the ApoE receptors compete with FE65
and subsequently alter the regulation of APP.
What is the biological significance of this proposed com-
plex? FE65 is known to interact with molecules important
in actin remodeling through its WW domains [9], promot-
ing the movement of neuronal growth cones and aiding in
cell motility [10]. Mice lacking FE65, VLDLR, or ApoER2
display defects in neuronal migration [11,40-42]. FE65 has
also been implicated in hippocampus-dependent learning
and long-term potentiation [43]. Additionally, ApoER2,
VLDLR, and APP knockout mice exhibit impaired learn-
ing and memory and LTP [44-47]. We and others have
also demonstrated that ApoER2 and APP play an impor-
tant role in dendritic spine formation [18,29,36,37,48,49].
Based on the literature and our findings, we hypothesize
that the interaction of FE65, ApoE receptors, and APP
could affect neuronal migration, learning and memory, as
well as dendritic spine formation. To support our hypoth-
esis, we observed that co-expression of FE65 and VLDLR
altered the pattern of VLDLR immunostaining along the
dendritic shaft and increased dendritic spine density com-
pared to controls (Figure 2). We are currently pursuing
these findings to understand whether a trimeric complex
versus a dimeric complex is formed, which functions each
is involved in, and how these protein complex’s regulate
the function of interest.
Conclusions
In summary, we found that FE65 associates with VLDLR
and alters its trafficking and processing. Additionally, the
association of FE65 with VLDLR CTF can translocate into
the nucleus similar to the APP CTF and FE65 complex.
Moreover, FE65 enhances the interaction between VLDLR
and APP, and this association affects the trafficking and
processing of both proteins. This work demonstrates a
novel complex between FE65, VLDLR, and APP, which
helps elucidate the role of FE65 in regulating transmem-
brane proteins like ApoE receptors and APP in the CNS.
Methods
Vector construction
We generated C-terminal tagged myc and C-terminal
tagged HA for full length VLDLR and C-terminal of
VLDLR. Recombinant DNA sequences were confirmed by
sequencing, and expression of correctly sized proteins was
confirmed by Western blot.
Cell lines and culture conditions
COS7 was maintained in Opti-MEM (Invitrogen) with
10% fetal bovine serum (FBS, Life Technologies, Inc.) in a
5% CO2 incubator. COS7 cells were transiently transfected
with 0.5 -1 ug of plasmid in FuGENE6 (Roche) according
to the manufacturer’s protocol and cultured 24 h in
DMEM containing 10% FBS. For co-transfections, cells
were similarly transfected with 0.5-1 ug of each plasmid in
Fugene 6 (Roche) and cultured 24 hr in DMEM with 10%
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serum free media (Invitrogen) and treated with indicated
compounds.
Isolation of nuclei
For isolation of nuclear fraction, cells were harvested and
200 μl of ice-cold CER1 was added to the cell pellet, vor-
texed vigorously to fully resuspend the cell pellet. The
tube was incubated on ice for 10 min, 11 μl of ice-cold
CER II was added, vortexed for 5 sec, and centrifuged for
5 min (16, 000 × g, 5 min). Immediately after the superna-
tant (cytoplasmic/membrane extract) fraction was trans-
ferred, and the insoluble (pellet) fraction was resuspended
in 100 ul of ice-cold NER. This was then vortexed for
15 sec, and returned to ice for continued vortexing for
15 sec every 10 min, for a total of 40 min. The sample was
then centrifuged for 10 min (16, 000 × g, 10 min) and the
supernatant (nuclear extract) fraction was immediately
transferred.
Antibodies
We used antibodies anti-HA (Abcam), anti-c-myc
(Abcam), anti-22C11 (Chemicon), anti-V5 (Chemicon),
and anti-FE65 (From Dr. Andre Goffinet). The anti-5F3
antibody was a kind gift of Dr. Dudley Strickland, the
C1/6.1 antibody was a kind gift from Dr. Paul Matthew,
and the VLDLR IIII antibody was a kind gift of
Dr. Guojun Bu. For analysis of secreted APP, we used
6E10 (identifying sAPPa) (Signet).
Quantification of VLDLR and APP proteolytic fragments
Secreted fragments were identified by western blot ana-
lysis of the media (sVLDLR, 5F3 antibody; sAPP, 6E10
antibody). CTF were measured by western blots of cell
lysates (VLDLR CTF, myc antibody; APP CTF, C1/6.1
antibody).
Culture and transfection of primary hippocampal neurons
Primary hippocampal neurons from embryonic day 18-
19 Sprague-Dawley rats were cultured at 150 cells/mm
2
as described [38]. Neurons were transfected at 14 days
in vitro (DIV) with GFP, APP-HA, VLDLR-Myc or
empty vector by lipofectamine 2000 (Invitrogen) (2 μg
DNA per well) according to manufacturers instructions.
Transcription of each insert was driven by the CMV
promoter.
Biotin-labeled cell surface proteins
COS7 cells were transiently transfected with VLDLR
and vector or VLDLR and FE65 in Fugene 6 (Roche)
and cultured 24 hrs in DMEM containing 10% FBS.
After 24 hr, cells were washed twice with PBS, and sur-
face proteins were labeled with Sulfo-NHS-SS-Biotin
500 ul at 500 ug/ml PBS (Pierce) under gentle shaking
at 4°C for 30 min. 50 ul of quenching solution was
added to cells at 4°C, which were then washed twice
with TBS. Cells were lysed in 500 ul lysis buffer, col-
lected with a cell scraper, disrupted by sonication on
ice, incubated for 30 min on ice, and clarified by centri-
fugation (10, 000 × g, 2 min). To isolate biotin-labeled
proteins, lysate was added to immobilized NeutrAvidin
TM Gel (50 ul) and incubated 1 hr at room temperature.
Gels were washed five times with wash buffer and incu-
bated 1 hr with SDS-PAGE sample buffer including
50 mM DTT. Elutions were analyzed by immunoblotting.
Immunostaining and live cell surface staining
Hippocampal cultured neurons were fixed in methanol at
-20°C for 10 min (for immunostaining of endogenous
synaptic markers). Antibodies for immunostaining were
incubated in GDB buffer (0.1% gelatin, 0.3% Triton X-100,
16 mM sodium phosphate pH 7.4, 450 mM NaCl).
Cell surface expression levels of VLDLR were performed
as described [17]. Live neuronal cultures were briefly incu-
bated (10 min) with the 5F3 antibody directed against
extracellular N-termini of VLDLR (10 μg/mL in condi-
tioned medium) to specifically label surface receptors,
then lightly fixed for 5 min in 4% paraformaldehyde (non-
permeabilizing conditions). After fixation, the surface-
remaining antibody-labeled protein was measured with
Alexa Fluor 555-conjugated anti-mouse secondary antibo-
dies for 2 hr. Immunostaining was quantified using Meta-
morph analysis of immunostaining intensity or punctate
number from Z-stacked images obtained with a Zeiss
LSM510 confocal microscope. Surface localization of
staining was also confirmed visually from these images.
Co-immunoprecipitations
Brain Lysates from 13 month old FE65 knockout mice and
wild-type littermate were homogenized in buffer contain-
ing 50 mm Tris-HCl, pH 8.0, 0.15 m NaCl, 1% Nonidet
P-40, and phosphatase and protease inhibitors (IP Buffer).
For immunoprecipitations, lysates were incubated over-
n i g h ta t4 ° Cw i t hA P Po rV L D L Ra n t i b o d ya n dp r o t e i n
G-Sepharose beads (Amersham Biosciences). The precipi-
tates were washed five times with lysis buffer and resus-
pended in SDS sample buffer.
GST pull down assay
The recombinant GST or GST-VLDLR CTF protein was
expressed in Escherichia coli BL21 strain, using the pGEX-
4B system as previously described (Kim, et al 2011). The
GST or GST-VLDLR CTF fusion protein was then puri-
fied using glutathione-agarose beads (Sigma), in accor-
dance with the manufacturer’s instructions. An equal
amount of GST or GST-VLDLR CTF fusion protein was
incubated overnight with brain lysates of wild-type mice
(n = 3 per each condition). After incubation, protein-A
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hours at 4°C on a rotator. Following incubation, the beads
were washed three times in ice-cold PBS and boiled with
Laemmli sample buffer.
Statistical analyses
Experiments were repeated a minimum of four times
unless otherwise noted. Data were analyzed using t-tests
with significance determined as p < 0.05. Descriptive
statistics were calculated with StatView 4.1 and dis-
played as an expressed mean ± S.E.M.
Additional material
Additional file 1: Figure S1. The FE65 PTB2 domain does not
interact with VLDLR. A. Constructs of FE65 with C-terminal GFP tags
containing only PTB2 (construct #1) and full length FE65 (construct # 2).
B. COS7 cells were transfected with VLDLR-myc and GFP, FE65 PTB2-GFP
or full length FE65-GFP. Cell lysates (100 ug) were immunoprecipitated
with 5F3 antibody (for VLDLR) and probed with an anti-GFP antibody (for
FE65). Full length FE65 immunoprecipitates with VLDLR, but not the FE65
containing only the PTB2 domain (first panel). Conversely, cell lysates
(100 ug) were immunoprecipitated with GFP (for FE65) and probed with
an anti-myc (for VLDLR) (second panel). Western blot analysis showing
comparable expression levels of the two FE65 constructs and VLDLR
(third and fourth panel).
Additional file 2: Figure S2. FE65 Knockout mice have increased
APP processing. 13 month old FE65 knockout mice or wild-type
littermates were immunoblotted with FE65, C1/6.1 (for APP), and b-actin.
FE65 knockout mice had increased levels of full length APP and APP CTF
compared to wild type littermates.
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